Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 491-497

  Lamanna, Nicole ^a   Jurcic, Joseph G ^a   Noy, Ariela ^a   Maslak, Peter ^a   Gencarelli, Alison N ^a   Panageas, Katherine S ^a   Heaney, Mark L ^a   Brentjens, Renier J ^a   Golde, David W ^a   Scheinberg, David A ^a   Zelenetz, Andrew D ^a   Weiss, Mark A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CATHETER INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; DRUG DOSE SEQUENCE; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; GENE MUTATION; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; INFECTION; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SKIN INFECTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRISOMY 12;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; VIDARABINE;

EID: 59149106873     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.4459     Document Type: Article

References (21)

1. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
2. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
3. Weiss M, Spiess T, Berman E, et al: Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 8:1290-1293, 1994
4. Elias L, Stock-Novack D, Head DR, et al: A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 7:361-365, 1993
5. O'Brien S, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
6. Weiss MA, Glenn M, Maslak P, et al: Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 14:1577-1582, 2000
7. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
8. Mayr C, Speicher MR, Kofler DM, et al: Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107:742-751, 2006
9. Samoszuk MK, Krailo M, Yan QH, et al: Limitations of numerical ratios for defining monoclonality of immunoglobulin light chains of B-cell lymphomas. Diagn Immunol 3:133-138, 1985
10. Dö hner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
11. Noy A, Verma R, Glenn M, et al: Clonotypic PCR confirms minimal residual disease (MRD) in CLL nodular PR: Preliminary results from a sequential treatment CLL protocol. Blood 97:1929-1936, 2001
12. National Cancer Institute: Common Toxicity Criteria. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
13. Keating MJ, O'Brien S, Albita M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
14. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
15. Byrd JC, Rai K, Peterson BL, et al: The addition of rituximab to fludarabine may prolong progress-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005
16. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP), for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 347:1432-1438, 1996
17. Leporrier M, Chevret S, Casin B, et al: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325, 2001
18. Eichorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006
19. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007
20. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomized controlled trial. Lancet 370:230-239, 2007
21. Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581, 2006